Literature DB >> 1793525

Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy.

A D Sperber1.   

Abstract

An 11-year-old boy with asthma had been receiving a controlled release theophylline preparation. He was prescribed fluvoxamine for a depressive disorder and within a week complained of severe headaches, tiredness and vomiting. His serum theophylline concentration had increased from 14.2 mg/L (shortly before fluvoxamine was started) to 27.4 mg/L. Fluvoxamine was withdrawn and theophylline concentrations decreased. Clomipramine was substituted for fluvoxamine with no further problems, and a later theophylline concentration was 13.7 mg/L. Competitive inhibition of hepatic microsomal enzymes by fluvoxamine may have been responsible for the elevated theophylline concentrations and toxicity observed in this case.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1793525     DOI: 10.2165/00002018-199106060-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  11 in total

1.  [Possible interaction between theophylline and fluvoxamine].

Authors:  P Diot; A P Jonville; F Gerard; M Bonnelle; E Autret; M Breteau; E Lemarie; M Lavandier
Journal:  Therapie       Date:  1991 Mar-Apr       Impact factor: 2.070

Review 2.  Clinical overview of serotonin reuptake inhibitors.

Authors:  K Rickels; E Schweizer
Journal:  J Clin Psychiatry       Date:  1990-12       Impact factor: 4.384

Review 3.  Therapeutic consequences of drug interactions with theophylline pharmacokinetics.

Authors:  J H Jonkman
Journal:  J Allergy Clin Immunol       Date:  1986-10       Impact factor: 10.793

4.  Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine.

Authors:  A J Martin; V M Tebbs; J J Ashford
Journal:  Pharmatherapeutica       Date:  1987

Review 5.  Pharmacological effects of serotonin reuptake inhibitors.

Authors:  B E Leonard
Journal:  J Clin Psychiatry       Date:  1988-08       Impact factor: 4.384

Review 6.  Serotonin and its place in the pathogenesis of depression.

Authors:  A J Coppen; D P Doogan
Journal:  J Clin Psychiatry       Date:  1988-08       Impact factor: 4.384

Review 7.  Fluvoxamine as an antiobsessional agent.

Authors:  W K Goodman; L H Price; S A Rasmussen; G R Heninger; D S Charney
Journal:  Psychopharmacol Bull       Date:  1989

8.  A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

Authors:  J P Feighner; W F Boyer; C H Meredith; G G Hendrickson
Journal:  Int Clin Psychopharmacol       Date:  1989-07       Impact factor: 1.659

Review 9.  Erratic absorption of theophylline from slow-release products in children.

Authors:  S J Szefler
Journal:  J Allergy Clin Immunol       Date:  1986-10       Impact factor: 10.793

10.  Clinical significance of day-night differences in serum theophylline concentration with special reference to Theo-Dur.

Authors:  M H Smolensky; P H Scott; W G Kramer
Journal:  J Allergy Clin Immunol       Date:  1986-10       Impact factor: 10.793

View more
  19 in total

1.  An interaction between carbamazepine and fluvoxamine.

Authors:  V Martinelli; A Bocchetta; A M Palmas; M Del Zompo
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

2.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Authors:  Kiyomi Ito; Koji Chiba; Masato Horikawa; Michi Ishigami; Naomi Mizuno; Jun Aoki; Yasumasa Gotoh; Takafumi Iwatsubo; Shin-ichi Kanamitsu; Motohiro Kato; Iichiro Kawahara; Kayoko Niinuma; Akiko Nishino; Norihito Sato; Yuko Tsukamoto; Kaoru Ueda; Tomoo Itoh; Yuichi Sugiyama
Journal:  AAPS PharmSci       Date:  2002

3.  Non-linear fluvoxamine disposition.

Authors:  O Spigset; K Granberg; S Hägg; E Söderström; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 6.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.

Authors:  K Brøsen
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 7.  Fluvoxamine. A review of global drug-drug interaction data.

Authors:  W Wagner; E W Vause
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 8.  Overview of the pharmacokinetics of fluvoxamine.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 9.  Antidepressant toxicity and the need for identification and concentration monitoring in overdose.

Authors:  B M Power; L P Hackett; L J Dusci; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

Review 10.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.